

Philip D Greenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9006353/publications.pdf>

Version: 2024-02-01

70
papers

11,125
citations

57631

44
h-index

102304

66
g-index

72
all docs

72
docs citations

72
times ranked

14214
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19. <i>Nature Biotechnology</i> , 2022, 40, 110-120.	9.4	81
2	Mac Cheever (1944â€“2021): a tribute to a life of achievement and service. , 2022, 10, e004433.		0
3	Multiple early factors anticipate post-acute COVID-19 sequelae. <i>Cell</i> , 2022, 185, 881-895.e20.	13.5	605
4	A New Year, A New Initiative. <i>Cancer Immunology Research</i> , 2022, 10, 2-2.	1.6	0
5	Targeting an alternate Wilmsâ€™ tumor antigen 1 peptide bypasses immunoproteasome dependency. <i>Science Translational Medicine</i> , 2022, 14, eabg8070.	5.8	12
6	Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. , 2022, 10, e003959.		10
7	Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease. <i>Gynecologic Oncology</i> , 2021, 160, 427-437.	0.6	4
8	A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	37
9	Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. <i>Cell</i> , 2020, 183, 1479-1495.e20.	13.5	449
10	Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	142
11	Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1412-1425.	1.6	26
12	T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. <i>Nature Medicine</i> , 2019, 25, 1064-1072.	15.2	226
13	Tracking the fate and origin of clinically relevant adoptively transferred CD8 ⁺ T cells in vivo. <i>Science Immunology</i> , 2017, 2, .	5.6	68
14	Obstacles Posed by the Tumor Microenvironment to T Cell Activity: A Case for Synergistic Therapies. <i>Cancer Cell</i> , 2017, 31, 311-325.	7.7	502
15	A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. <i>Blood</i> , 2017, 130, 2410-2419.	0.6	44
16	MicroRNA-150 modulates intracellular Ca ²⁺ levels in naïve CD8+ T cells by targeting TMEM20. <i>Scientific Reports</i> , 2017, 7, 2623.	1.6	9
17	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. <i>Immunity</i> , 2016, 45, 389-401.	6.6	496
18	Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. <i>Journal of Experimental Medicine</i> , 2016, 213, 1133-1139.	4.2	78

#	ARTICLE	IF	CITATIONS
19	T-Cell Therapy Using Interleukin-21 ⁺ Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. <i>Journal of Clinical Oncology</i> , 2016, 34, 3787-3795.	0.8	98
20	Pancreatic Cancer: Planning Ahead for Metastatic Spread. <i>Cancer Cell</i> , 2016, 29, 774-776.	7.7	9
21	TCR contact residue hydrophobicity is a hallmark of immunogenic CD8 ⁺ T cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1754-62.	3.3	200
22	New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 5191-5197.	3.2	29
23	T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2015, 28, 638-652.	7.7	168
24	Ontogeny of Recognition Specificity and Functionality for the Broadly Neutralizing Anti-HIV Antibody 4E10. <i>PLoS Pathogens</i> , 2014, 10, e1004403.	2.1	27
25	Re ⁺ adapting T cells for cancer therapy: from mouse models to clinical trials. <i>Immunological Reviews</i> , 2014, 257, 145-164.	2.8	67
26	Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8 ⁺ T cells. <i>Nature Protocols</i> , 2014, 9, 950-966.	5.5	109
27	Tolerance and exhaustion: defining mechanisms of T cell dysfunction. <i>Trends in Immunology</i> , 2014, 35, 51-60.	2.9	513
28	Stromal reengineering to treat pancreas cancer. <i>Carcinogenesis</i> , 2014, 35, 1451-1460.	1.3	108
29	Molecular Pathways: Myeloid Complicity in Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5157-5170.	3.2	44
30	Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. <i>Gut</i> , 2014, 63, 1769-1781.	6.1	272
31	MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 195-203.e4.	1.5	62
32	Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8 ⁺ T-Cell Tolerance. <i>Cancer Research</i> , 2013, 73, 605-616.	0.4	41
33	Transferred WT1-Reactive CD8 ⁺ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients. <i>Science Translational Medicine</i> , 2013, 5, 174ra27.	5.8	280
34	Cell-Intrinsic Abrogation of TGF- β 2 Signaling Delays but Does Not Prevent Dysfunction of Self/Tumor-Specific CD8 T Cells in a Murine Model of Autochthonous Prostate Cancer. <i>Journal of Immunology</i> , 2012, 189, 3936-3946.	0.4	22
35	Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State. <i>Science</i> , 2012, 335, 723-727.	6.0	149
36	Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. <i>Blood</i> , 2012, 119, 5492-5501.	0.6	66

#	ARTICLE	IF	CITATIONS
37	HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. <i>Blood</i> , 2011, 117, 5391-5402.	0.6	44
38	Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. <i>Blood</i> , 2011, 117, 6542-6551.	0.6	54
39	Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity. <i>Blood</i> , 2011, 118, 5476-5486.	0.6	113
40	Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 173-186.	2.0	37
41	Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 161-171.	2.0	67
42	Retinoic Acid as a Vaccine Adjuvant Enhances CD8 ⁺ T Cell Response and Mucosal Protection from Viral Challenge. <i>Journal of Virology</i> , 2011, 85, 8316-8327.	1.5	82
43	Ralph M. Steinman: A man, a microscope, a cell, and so much more. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20871-20872.	3.3	1
44	SHP-1 in T Cells Limits the Production of CD8 Effector Cells without Impacting the Formation of Long-Lived Central Memory Cells. <i>Journal of Immunology</i> , 2010, 185, 3256-3267.	0.4	53
45	Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 3722-3734.	3.9	74
46	Adoptive Immunotherapy of Disseminated Leukemia With TCR-transduced, CD8+ T Cells Expressing a Known Endogenous TCR. <i>Molecular Therapy</i> , 2009, 17, 742-749.	3.7	39
47	Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain V1±V1 ² fragments. <i>Molecular Immunology</i> , 2009, 46, 902-916.	1.0	51
48	Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2008, 73A, 1043-1049.	1.1	58
49	Peripheral CD8+ T Cell Tolerance to Self-Proteins Is Regulated Proximally at the T Cell Receptor. <i>Immunity</i> , 2008, 28, 662-674.	6.6	44
50	Hepatitis C Virus Immune Escape via Exploitation of a Hole in the T Cell Repertoire. <i>Journal of Immunology</i> , 2008, 181, 6435-6446.	0.4	61
51	Induction of Tolerance in CD8+ T Cells to a Transgenic Autoantigen Expressed in the Liver Does Not Require Cross-Presentation. <i>Journal of Immunology</i> , 2007, 178, 6849-6860.	0.4	24
52	Facilitating matched pairing and expression of TCR chains introduced into human T cells. <i>Blood</i> , 2007, 109, 2331-2338.	0.6	318
53	Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. <i>Blood</i> , 2007, 110, 201-210.	0.6	383
54	Adoptive Cellular Therapy for Follicular Lymphoma Using Genetically-Modified Autologous CD20-Specific T Cells. <i>Blood</i> , 2007, 110, 499-499.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. <i>Nature Medicine</i> , 2006, 12, 335-341.	15.2	221
56	In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. <i>Journal of Immunological Methods</i> , 2006, 310, 40-52.	0.6	111
57	CD27 Expression Promotes Long-Term Survival of Functional Effector Memory CD8+ Cytotoxic T Lymphocytes in HIV-infected Patients. <i>Journal of Experimental Medicine</i> , 2004, 200, 1407-1417.	4.2	113
58	Restoration of CD28 Expression in CD28 ^{hi} CD8+ Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production. <i>Journal of Experimental Medicine</i> , 2003, 198, 947-955.	4.2	142
59	Selective Delivery of Augmented IL-2 Receptor Signals to Responding CD8+ T Cells Increases the Size of the Acute Antiviral Response and of the Resulting Memory T Cell Pool. <i>Journal of Immunology</i> , 2002, 169, 4990-4997.	0.4	35
60	CD8+ T Cell Tolerance to a Tumor-associated Antigen Is Maintained at the Level of Expansion Rather than Effector Function. <i>Journal of Experimental Medicine</i> , 2002, 195, 1407-1418.	4.2	96
61	Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma. <i>Journal of Experimental Medicine</i> , 2000, 192, 1637-1644.	4.2	414
62	Expression of Herpes Simplex Virus ICP47 and Human Cytomegalovirus US11 Prevents Recognition of Transgene Products by CD8+ Cytotoxic T Lymphocytes. <i>Journal of Virology</i> , 2000, 74, 4465-4473.	1.5	5
63	Immunization against SIVmne in macaques using multigenic DNA vaccines. <i>Journal of Medical Primatology</i> , 1999, 28, 206-213.	0.3	19
64	Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. <i>Nature Medicine</i> , 1999, 5, 677-685.	15.2	1,033
65	Principles for Adoptive T Cell Therapy of Human Viral Diseases. <i>Annual Review of Immunology</i> , 1995, 13, 545-586.	9.5	235
66	Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor. <i>New England Journal of Medicine</i> , 1995, 333, 1038-1044.	13.9	1,756
67	Immune Responses Elicited by Recombinant Vaccinia-Human Immunodeficiency Virus (HIV) Envelope and HIV Envelope Protein: Analysis of the Durability of Responses and Effect of Repeated Boosting. <i>Journal of Infectious Diseases</i> , 1994, 169, 41-47.	1.9	51
68	Genetic Modification of T Cell Clones to Improve the Safety and Efficacy of Adoptive T Cell Therapy. <i>Novartis Foundation Symposium</i> , 1994, 187, 212-228.	1.2	0
69	Effect of Interleukin-2 on Biodistribution of Monoclonal Antibody in Tumor and Normal Tissues in Mice Bearing SL-2 Thymoma. <i>Journal of the National Cancer Institute</i> , 1992, 84, 109-113.	3.0	13
70	The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. <i>Journal of Immunological Methods</i> , 1990, 128, 189-201.	0.6	322